Lexeo raises $80M in private placement; cash runway into 2028

Lexeo Therapeutics, Inc.

Gross proceeds ~$80M from sale of 20.79M shares and warrants at $2.8825/unit.
Pre-funded warrants for 6.96M shares at $0.0001; common warrants expire May 28, 2029.
Financing co-led by Frazier Life Sciences and Janus Henderson; J.P. Morgan, Oppenheimer placement agents.
Proceeds to fund clinical programs including LX2006 efficacy readout expected by 2027.
Private placement expected to close May 28, 2025; resale registration to be filed by June 27, 2025.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.